drugset / Trial / NCT03354429

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

NCT03354429

Phase 3 Completed 11016 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events

Timeline

Start
2018-01-22
Primary completion
2019-12-13
Completion
2019-12-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 90 mg